Pentadeca arginate (PDA): the physician-accessible BPC-157 alternative
A close cousin of BPC-157 — with very different regulatory paperwork and a very thin human evidence base.
TL;DR
- Pentadeca arginate (PDA) is a synthetic analog of the BPC-157 sequence with an added arginate salt group intended to improve stability.
- PDA is currently being prepared by some state-licensed 503A compounding pharmacies. BPC-157 is in FDA Category 2 and generally cannot be compounded.
- The human evidence base for PDA itself is thin. Patient expectations should match the literature, not the marketing.
What it is
PDA stands for pentadeca arginate. "Pentadeca" means 15 amino acids — the same length as BPC-157 — and "arginate" refers to a salt of the amino acid arginine added to the molecule. The idea behind PDA is to take a sequence closely related to BPC-157 and pair it with a chemical tweak intended to improve stability in compounding (Sikiric et al., 2005). Critically, PDA and BPC-157 have different regulatory status. PDA is being prepared by some state-licensed 503A pharmacies; BPC-157 currently sits on the FDA's Category 2 list (FDA 503A Bulks List).
How it works
Think of BPC-157 as the parent recipe and PDA as a slightly different version of the same dish, salted differently to hold its shape longer in a hot pan. The underlying flavor — the proposed gut and tissue-repair signaling — is similar in concept. Whether it cooks the same way in human bodies is a separate question the published evidence has not answered yet.
Who asks about it
People come to this topic after their clinician mentions PDA when BPC-157 is not available. Many assume the two are interchangeable. They are related, but they are not the same drug, not the same legal status, and not the same evidence base.
What the research says
The bulk of the published evidence is on BPC-157 in rodents — not on PDA in humans. PDA's specific human evidence base is thin. Where PDA is being used clinically, it is being used on the strength of BPC-157's preclinical data and on stability assumptions, not on Phase 3 trial results in PDA itself. About 1 in 10 compounds that look promising in animals end up showing the same effect in human trials, on average across drug categories — a base rate that applies to PDA's underlying premise.
What to know before considering it
PDA is generally well-tolerated in early clinical reports. Side-effect data is limited, and patient-specific dosing varies by physician. PDA requires a valid prescription and a licensed clinician evaluation. Compounded preparations are made by state-licensed 503A pharmacies and are not FDA-approved as finished drugs.
The Halftime POV
PDA is interesting because it is physician-accessible while BPC-157 is in regulatory limbo. That is a real practical difference. It is not, however, a substitute for the human evidence base that neither compound yet has.
Related reading:
- Why BPC-157 animal studies don't automatically translate to humans
- BPC-157 availability in 2026: where things actually stand
- How to choose a quality peptide compounding pharmacy: the quality signals
FAQ
Q: What is pentadeca arginate? A: Pentadeca arginate (PDA) is a synthetic peptide modeled on the BPC-157 sequence with an added arginate salt group intended to improve stability. It is discussed in clinical practice as a physician-accessible analog of BPC-157.
Q: Is PDA the same as BPC-157? A: No. They share a closely related amino acid sequence and the same parent research line, but they are different compounds with different regulatory status. PDA is being prepared by some state-licensed 503A compounding pharmacies; BPC-157 is currently in FDA Category 2.
Q: Is PDA FDA-approved? A: No. Pentadeca arginate is not FDA-approved as a finished drug. The compounded version is prepared by state-licensed 503A pharmacies and is not itself FDA-approved.
Q: Where is the human research? A: Human clinical evidence on PDA specifically is limited. The interest is largely extrapolated from BPC-157 rodent literature, which is itself thin in humans. Patients should set expectations accordingly.
Disclaimer
As of May 2026, BPC-157, which is discussed in this article as the parent sequence of pentadeca arginate (PDA), is classified by the FDA as Category 2, which means it is not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning several peptides to Category 1 pending formal FDA Federal Register notice. Pentadeca arginate itself is not FDA-approved as a finished drug. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health's published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What is pentadeca arginate?
Pentadeca arginate (PDA) is a synthetic peptide modeled on the BPC-157 sequence with an added arginate salt group intended to improve stability. It is discussed in clinical practice as a physician-accessible analog of BPC-157.
Is PDA the same as BPC-157?
No. They share a closely related amino acid sequence and the same parent research line, but they are different compounds with different regulatory status. PDA is being prepared by some state-licensed 503A compounding pharmacies; BPC-157 is currently in FDA Category 2.
Is PDA FDA-approved?
No. Pentadeca arginate is not FDA-approved as a finished drug. The compounded version is prepared by state-licensed 503A pharmacies and is not itself FDA-approved.
Where is the human research?
Human clinical evidence on PDA specifically is limited. The interest is largely extrapolated from BPC-157 rodent literature, which is itself thin in humans. Patients should set expectations accordingly.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.